Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02437279
Recruitment Status : Unknown
Verified July 2017 by The Netherlands Cancer Institute.
Recruitment status was:  Active, not recruiting
First Posted : May 7, 2015
Last Update Posted : July 18, 2017
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Brief Summary:
This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.

Condition or disease Intervention/treatment Phase
Stage III Skin Melanoma Procedure: Surgery of the tumor Drug: Infusion with ipilimumab 3 mg/kg q3wks Drug: Infusion with nivolumab 1 mg/kg q3wks Phase 1

Detailed Description:

Patients with stage III melanoma with palpable disease, naïve for CTLA-4/PD-1/PD-L1 immunotherapy, will be treated either post-surgery for 12 weeks with the combination of ipilimumab+nivolumab or in a split design for 6 weeks upfront surgery and for 6 weeks postsurgery. It is a two-arm Phase 1b feasibility trial consisting of 20 patients, 10 in each arm.

At different timepoints tumor biopsies and blood for PBMCs will be taken for translational research. Also scans will be done on specific timepoints.

The study will be held to determine safety, feasibility, and the immune-activating capacity of short-term combined neo-adjuvant and adjuvant ipilimumab + nivolumab. And to determine relapse free survival (RFS), any late adverse events, pharmacokinetics/pharmacodynamics, and the correlation between RFS and changes in neo-antigen specific T cell response.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients
Actual Study Start Date : August 12, 2015
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : April 2018


Arm Intervention/treatment
Active Comparator: Arm A
Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
Procedure: Surgery of the tumor
Drug: Infusion with ipilimumab 3 mg/kg q3wks
Drug: Infusion with nivolumab 1 mg/kg q3wks
Active Comparator: Arm B
A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
Procedure: Surgery of the tumor
Drug: Infusion with ipilimumab 3 mg/kg q3wks
Drug: Infusion with nivolumab 1 mg/kg q3wks



Primary Outcome Measures :
  1. The alteration in magnitude of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood [ Time Frame: 12 weeks from baseline ]
    To this purpose the immunogenic mutational load of each patient's melanoma will be determined by DNA and RNA sequencing from baseline biopsies (3x14g, 5ug tumor DNA). Proteasomal degradation and peptide presentation in HLA will be predicted in silico. MHC-tetramer staining containing the predicted peptides will be done as described before [2]. In addition, the effect of therapy on intratumoral T cell responses to obtain better insight into the mode of action of therapy will be analyzed. Identified neo-antigen specific T cells will be analyzed with respect to their phenotype and immunologic function (intracellular cytokine staining, lytic function as determined by CD107 staining, and coculture with APC presenting the cognate antigen).

  2. Safety as measured by SUSARs. [ Time Frame: 12 weeks from baseline ]
  3. The alteration in breadth of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood [ Time Frame: 12 weeks from baseline ]
    To this purpose the immunogenic mutational load of each patient's melanoma will be determined by DNA and RNA sequencing from baseline biopsies (3x14g, 5ug tumor DNA). Proteasomal degradation and peptide presentation in HLA will be predicted in silico. MHC-tetramer staining containing the predicted peptides will be done as described before [2]. In addition, the effect of therapy on intratumoral T cell responses to obtain better insight into the mode of action of therapy will be analyzed. Identified neo-antigen specific T cells will be analyzed with respect to their phenotype and immunologic function (intracellular cytokine staining, lytic function as determined by CD107 staining, and coculture with APC presenting the cognate antigen).

  4. Feasibility as measured adherence to the timelines in the study protocol. [ Time Frame: 12 weeks from baseline ]

Secondary Outcome Measures :
  1. Recurrence Free Survival, as determined according to RECIST 1.1 criteria. [ Time Frame: Until progression, median 10 months. ]
  2. Rate of adverse events and late adverse events [ Time Frame: Until end of follow-up, median 3 years. ]
  3. Type of adverse events and late adverse events [ Time Frame: Until end of follow-up, median 3 years. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults at least 18 years of age
  • World Health Organization (WHO) Performance Status 0 or 1
  • Histologically confirmed stage IIIB metastatic cutaneous melanoma, palpable disease (non-transit only) of the axilla or groin
  • Patient willing to undergo triple tumor biopsies during screening and in case of disease progression
  • No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1
  • No immunosuppressive medications within 6 months prior study inclusion
  • Presence of at least two of the defined HLA alleles (Table 1, see appendix)
  • Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils

    ≥1.5x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, Creatinine ≤1.5x ULN, AST ≤1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤1.5 X ULN

  • normal LDH
  • Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug
  • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of ipilimumab+nivolumab
  • Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product
  • Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception

Exclusion Criteria:

  • Distantly metastasized melanoma
  • Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy
  • Prior CTLA-4 or PD-1/PD-L1 targeting immunotherapy
  • Radiotherapy prior or post surgery within this trial
  • Patients will be excluded if they are positive test for hepatitis B virus surface antigen (HBVsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
  • Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Allergies and Adverse Drug Reaction

    • History of allergy to study drug components
    • History of severe hypersensitivity reaction to any monoclonal antibody
  • Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events;
  • Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
  • Use of other investigational drugs before study drug administration 30 days and 5 half-times before study inclusion
  • Pregnant or nursing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02437279


Locations
Layout table for location information
Netherlands
Netherlands Cancer Institute
Amsterdam, NH, Netherlands, 1066CX
Sponsors and Collaborators
The Netherlands Cancer Institute
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Christian Blank, MD PhD The Netherlands Cancer Institute

Layout table for additonal information
Responsible Party: The Netherlands Cancer Institute
ClinicalTrials.gov Identifier: NCT02437279    
Other Study ID Numbers: N14OPC
CA209-278 ( Other Grant/Funding Number: BMS )
NL51280.031.14 ( Registry Identifier: CCMO register )
First Posted: May 7, 2015    Key Record Dates
Last Update Posted: July 18, 2017
Last Verified: July 2017
Keywords provided by The Netherlands Cancer Institute:
Palpable
Stage III
Skin melanoma
Ipilimumab
Nivolumab
Surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents